New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
08:08 EDTHRTXHeron Therapeutics reports Q2 EPS (78c), consensus (74c)
The company said, "The increase in net loss was primarily due to the initiation of a Phase 3 label expansion study of SUSTOL in Q1 and expenses related to new product development, including our new program targeting the relief of post-surgical pain, which was initiated in November 2013."
News For HRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
08:44 EDTHRTXHeron Therapeutics management to meet with Brean Capital
Subscribe for More Information
July 23, 2015
08:08 EDTHRTXHeron Therapeutics initiates second Phase 2 HTX-011 trial
Heron Therapeutics announced that it has initiated a second Phase 2 clinical trial of HTX-011. HTX-011, which utilizes Heronís proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The placebo-controlled, dose-finding, Phase 2 clinical trial in approximately 60 patients undergoing inguinal hernia repair will evaluate the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine combined with meloxicam, compared to placebo. HTX-011 is also currently being evaluated in a placebo-controlled, dose-finding, Phase 2 clinical trial in patients undergoing bunionectomy. In a previously completed, placebo-controlled, Phase 1 clinical trial, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam, with therapeutically relevant plasma bupivacaine levels sustained for 2-3 days.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use